COX-2 inhibitors may prevent severe acute pancreatitis
The management of Severe acute pancreatitis is complicated because of the limited understanding of the pathogenesis, multiple risk factors, and few treatment modalities.;
China: Cyclooxygenase-2 (COX-2)-inhibitor treatment may reduce severe acute pancreatitis (SAP) by nearly half in at-risk patients, according to a new randomized controlled trial conducted by doctors at Sichuan University, China and published in American Journal of Gastroenterology.
Severe acute pancreatitis (SAP) is associated with high morbidity and mortality due to the development of pancreatic and extra-pancreatic necrosis, their subsequent infection and multisystem organ failure (MOF). The management of SAP is complicated because of the limited understanding of the pathogenesis, multiple risk factors, and also the availability of very few treatment modalities.
Dr Huang and his colleagues of West China Hospital and Sichuan University in Chengdu, China., based on an experimental evidence showing overexpression of COX-2 in acute pancreatitis, and that blocking COX-2 reduced pancreatitis severity, conducted a randomized trial in which 190 patients with predicted SAP received standard treatment or standard treatment plus 40 mg per day of parecoxib intravenously for 3 days, followed by 200 mg of celecoxib orally or through a feeding tube every day for 1 week.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.